Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
DrugDrug NameDrug Indication
DB00874GuaifenesinUsed to assist the expectoration of phlegm from the airways in acute respiratory tract infections.
DB01423SteproninStrepronin is a mucolytic (expectorant) drug.
DB04339CarbocisteineUsed to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis.
DB05057ErdosteineFro the treatment of chronic bronchitis in adults.
DB06151AcetylcysteineAcetylcysteine is used mainly as a mucolytic and in the management of paracetamol (acetaminophen) overdose.
DB06742AmbroxolAmbroxol is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply.
DB08939LetosteineNot Available
DB08990EprazinoneNot Available
DB09019BromhexineNot Available
DB13163Terpin hydrateTerpin hydrate is an expectorant, used in the treatment of acute and chronic bronchitis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease, infectious and inflammatory diseases of the upper respiratory tract. It is typically formulated with an antitussive (e.g., codeine) as a combined preparation.
DB00003Dornase alfaUsed as adjunct therapy in the treatment of cystic fibrosis.
DB00742MannitolUsed for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.
DB03852EucalyptolNot Available
DB06439TyloxapolUsed as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.
DB06823TioproninTiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization.
DB13293IpecacuanhaNot Available
DB13735GuaiacolsulfonateNot Available
DB09125Potassium CitrateFor the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.